Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479156 | 1.00 | POLB (0.39) | POLBGFERAVPR1AALDH1A1KDM4E | |
| SCHEMBL11418047 | 0.73 | CYP11B2 (0.38) | AVPR1AALDH1A1HSD17B10TSHRL3MBTL1 | |
| SCHEMBL1097697 | 0.72 | UTS2R (0.39) | POLBGFERALDH1A1KDM4EHPGD | |
| SCHEMBL23811488 | 0.70 | DRD2 (0.33) | AVPR1A | |
| SCHEMBL30504151 | 0.70 | AVPR1A (0.39) | AVPR1AL3MBTL1KMT2A | |
| SCHEMBL29803988 | 0.70 | POLB (0.51) | POLBGFERALDH1A1KDM4EGAA | |
| SCHEMBL23649510 | 0.70 | POLB (0.51) | POLBGFERALDH1A1KDM4EGAA | |
| SCHEMBL10146421 | 0.70 | — | — | |
| SCHEMBL31069046 | 0.70 | — | — | |
| SCHEMBL21708059 | 0.69 | CNR2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | POLB 2326/4885GFER 3246/4885AVPR1A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.